| 1 |
Kizilaslan EZ, Ghadge NM, Martinez A, Bass M, Winayak R, Mathew M, Amin R, Khan M, Kizilbash N. Acute Intermittent Porphyria’s Symptoms and Management: A Narrative Review. Cureus 2023. [DOI: 10.7759/cureus.36058] [Reference Citation Analysis]
|
| 2 |
Souza PVS, Afonso G, de Rezende Pinto WBV, de Lima Serrano P, de Mattos Lombardi Badia B, Farias IB, Dos Santos Jorge AC, Machado RIL, Pinto IFN, Barros GB, de Oliveira HB, Calil SR, Franz C, Oliveira ASB. Brazilian registry of patients with porphyria: REBRAPPO study. Orphanet J Rare Dis 2023;18:49. [PMID: 36890577 DOI: 10.1186/s13023-023-02653-1] [Reference Citation Analysis]
|
| 3 |
Cunningham W, Chilaka J, Edwards N, Poulton K. Acute intermittent porphyria: A rare cause of syndrome of inappropriate antidiuretic hormone secretion. J R Coll Physicians Edinb 2023;:14782715231161499. [PMID: 36883342 DOI: 10.1177/14782715231161499] [Reference Citation Analysis]
|
| 4 |
Lissing M, Vassiliou D, Floderus Y, Harper P, Yan J, Hagström H, Sardh E, Wahlin S. Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals. J Inherit Metab Dis 2023;46:286-99. [PMID: 36546345 DOI: 10.1002/jimd.12583] [Reference Citation Analysis]
|
| 5 |
Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023;164:484-91. [PMID: 36642627 DOI: 10.1053/j.gastro.2022.11.034] [Reference Citation Analysis]
|
| 6 |
Diehl-wiesenecker E, Blaschke S, Wohmann N, Kubisch I, Stauch T, Mainert M, Helm F, von Wegerer S, Pittrow D, Frank J, Stölzel U, Somasundaram R. Detect Acute Porphyrias in Emergency Departments (DePorED) – A pilot study.. [DOI: 10.21203/rs.3.rs-2397524/v1] [Reference Citation Analysis]
|
| 7 |
Ramzan A, Cao JJL, Frazer JS, Stein P, Ahmad S. A Case of Acute Intermittent Porphyria Leading to Severe Disability in a Young 21-Year-Old Female. Cureus 2023;15:e34757. [PMID: 36909084 DOI: 10.7759/cureus.34757] [Reference Citation Analysis]
|
| 8 |
Kazamel M, Pischik E, Desnick RJ. Pain in acute hepatic porphyrias: Updates on pathophysiology and management. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1004125] [Reference Citation Analysis]
|
| 9 |
Song C, Liu Y. A high urinary urobilinogen / serum total bilirubin ratio reported in abdominal pain patients can indicate acute hepatic porphyria.. [DOI: 10.21203/rs.3.rs-587707/v3] [Reference Citation Analysis]
|
| 10 |
Jericó D, Córdoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Ávila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel) 2022;12. [PMID: 36430993 DOI: 10.3390/life12111858] [Reference Citation Analysis]
|
| 11 |
Vachiravit Sriprakoon, Chalisa Ittagornpunth, Nakorn Puapaiboon, Aekasit Bunyahathaipat, Punnapat Piriyanon, Sookkasem Khositseth, Kitiwan Rojnueangnit. Acute Intermittent Porphyria: Complete Phenotype in a Patient with p.Arg173Trp Variant in Thailand. Am J Case Rep 2022;23. [PMID: 36329616 DOI: 10.12659/AJCR.937695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Dickey A, Wheeden K, Lyon D, Burrell S, Hegarty S, Falchetto R, Williams ER, Barman-Aksözen J, DeCongelio M, Bulkley A, Matos JE, Mnif T, Mora J, Ko JJ, Meninger S, Lombardelli S, Nance D. Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) study. JIMD Rep 2023;64:104-13. [PMID: 36636593 DOI: 10.1002/jmd2.12343] [Reference Citation Analysis]
|
| 13 |
Horie Y, Yasuoka Y, Adachi T. Clinical features of Japanese patients with acute hepatic porphyria. JIMD Rep 2023;64:71-8. [PMID: 36636592 DOI: 10.1002/jmd2.12336] [Reference Citation Analysis]
|
| 14 |
Ventura P, Sardh E, Longo N, Balwani M, Plutzky J, Gouya L, Phillips J, Rhyee S, Fanelli MJ, Sweetser MT, Petrides PE. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Expert Rev Gastroenterol Hepatol 2022;16:879-94. [PMID: 35929959 DOI: 10.1080/17474124.2022.2110469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Wang B, Ventura P, Takase KI, Thapar M, Cassiman D, Kubisch I, Liu S, Sweetser MT, Balwani M. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. Orphanet J Rare Dis 2022;17:327. [PMID: 36028858 DOI: 10.1186/s13023-022-02463-x] [Reference Citation Analysis]
|
| 16 |
Coffin B, Duboc H. Review article: diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome. Aliment Pharmacol Ther 2022;56:419-35. [PMID: 35656644 DOI: 10.1111/apt.17064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Petrides PE. Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know. Diagnostics 2022;12:1618. [DOI: 10.3390/diagnostics12071618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Kubisch I, Stölzel U. Porphyrien erkennen und therapieren. Gastro-News 2022;9:34-39. [DOI: 10.1007/s15036-022-2500-8] [Reference Citation Analysis]
|
| 19 |
Ricci A, Sandri G, Marcacci M, Di Pierro E, Granata F, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Endothelial Dysfunction in Acute Hepatic Porphyrias. Diagnostics 2022;12:1303. [DOI: 10.3390/diagnostics12061303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Schulenburg-Brand D, Stewart F, Stein P, Rees D, Badminton M. Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. J Clin Pathol 2022:jclinpath-2021-207647. [PMID: 35584894 DOI: 10.1136/jclinpath-2021-207647] [Reference Citation Analysis]
|
| 21 |
Francesca G, Nicolli A, Colaiocco A, Di Pierro E, Graziadei G. Psychological Aspect and Quality of Life in Porphyrias: A Review. Diagnostics 2022;12:1193. [DOI: 10.3390/diagnostics12051193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Ventura P, Ricci A. Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2075848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med 2022;291:593-610. [PMID: 35067977 DOI: 10.1111/joim.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 24 |
Marcacci M, Ricci A, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives. Orphanet J Rare Dis 2022;17:160. [PMID: 35392955 DOI: 10.1186/s13023-022-02314-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Gomez-Gomez A, Aguilera P, Langohr K, Casals G, Pavon C, Marcos J, To-Figueras J, Pozo OJ. Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics. Int J Mol Sci 2022;23:3219. [PMID: 35328641 DOI: 10.3390/ijms23063219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Baumann K, Kauppinen R. Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy. Molecular Genetics and Metabolism Reports 2022;30:100842. [DOI: 10.1016/j.ymgmr.2022.100842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Córdoba KM, Serrano-Mendioroz I, Jericó D, Merino M, Jiang L, Sampedro A, Alegre M, Corrales F, Garrido MJ, Martini PGV, Lanciego JL, Prieto J, Berraondo P, Fontanellas A. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria. Sci Transl Med 2022;14:eabc0700. [PMID: 35020410 DOI: 10.1126/scitranslmed.abc0700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 28 |
Vassiliou D, Sardh E. Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies. J Intern Med 2022;291:81-94. [PMID: 34411356 DOI: 10.1111/joim.13376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Stölzel U, Kubisch I, Stauch T, Schuppan D. Disorders of Heme Metabolism. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases 2022. [DOI: 10.1007/978-3-030-67727-5_57] [Reference Citation Analysis]
|
| 30 |
Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiró P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E; ENVISION Investigators. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int 2022;42:161-72. [PMID: 34717041 DOI: 10.1111/liv.15090] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 31 |
Poli A, Schmitt C, Moulouel B, Mirmiran A, Talbi N, Rivière S, Cerutti D, Bouchoule I, Faivre A, Grobost V, Douillard C, Duchêne F, Fiorentino V, Dupré T, Manceau H, Peoc'h K, Puy H, Lefebvre T, Gouya L. Givosiran in acute intermittent porphyria: A personalized medicine approach. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 32 |
Ricci A, Di Pierro E, Marcacci M, Ventura P. Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias. Diagnostics (Basel) 2021;11:2205. [PMID: 34943446 DOI: 10.3390/diagnostics11122205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 33 |
Jud P, Hackl G, Reisinger AC, Horvath A, Eller P, Stadlbauer V. Red urine and a red herring - diagnosing rare diseases in the light of the COVID-19 pandemic. Z Gastroenterol 2021. [PMID: 34768287 DOI: 10.1055/a-1659-4481] [Reference Citation Analysis]
|
| 34 |
Gerischer LM, Scheibe F, Nümann A, Köhnlein M, Stölzel U, Meisel A. Acute porphyrias - A neurological perspective. Brain Behav 2021;11:e2389. [PMID: 34661997 DOI: 10.1002/brb3.2389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Kuo HC, Lin CN, Tang YF. Prophylactic Heme Arginate Infusion for Acute Intermittent Porphyria. Front Pharmacol 2021;12:712305. [PMID: 34690757 DOI: 10.3389/fphar.2021.712305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
de Souza PVS, Badia BML, Farias IB, Pinto WBVR, Oliveira ASB. Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations. Front Neurosci 2021;15:715523. [PMID: 34646118 DOI: 10.3389/fnins.2021.715523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
García Morillo JS, Rodríguez Suárez S, Campos Coroa J. Quality of life and perceived health in patients with porphyrias. Med Clin (Barc) 2021;157:344-5. [PMID: 33317874 DOI: 10.1016/j.medcli.2020.08.014] [Reference Citation Analysis]
|
| 38 |
Vassiliou D, Sardh E. Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase. J Intern Med 2021;290:928-30. [PMID: 34184789 DOI: 10.1111/joim.13341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 39 |
García Morillo JS, Rodríguez Suárez S, Campos Coroa J. Quality of life and perceived health in patients with porphyrias. Medicina Clínica (English Edition) 2021;157:344-345. [DOI: 10.1016/j.medcle.2021.09.003] [Reference Citation Analysis]
|
| 40 |
Anderson KE, Desnick RJ, Stewart MF, Ventura P, Bonkovsky HL. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features that should Prompt Specific Diagnostic Testing. Am J Med Sci 2021:S0002-9629(21)00337-2. [PMID: 34606756 DOI: 10.1016/j.amjms.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 41 |
Vassiliou D, Sardh E, Harper P, Simon AR, Clausen VA, Najafian N, Robbie GJ, Agarwal S. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clin Pharmacol Ther 2021;110:1250-60. [PMID: 34510420 DOI: 10.1002/cpt.2419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 42 |
Gilles A, Vermeersch S, Vermeersch P, Wolff F, Cotton F, Tilleux S, Cassiman D. Expert consensus statement on acute hepatic porphyria in Belgium. Acta Clin Belg 2021;:1-7. [PMID: 34369323 DOI: 10.1080/17843286.2021.1961056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Connolly MP, Kotsopoulos N, Vermeersch S, Patris J, Cassiman D. Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework. Orphanet J Rare Dis 2021;16:346. [PMID: 34348763 DOI: 10.1186/s13023-021-01966-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 44 |
Stölzel U, Schuppan D. [New therapeutic option for acute hepatic porphyrias]. Dtsch Med Wochenschr 2021;146:955-8. [PMID: 34344029 DOI: 10.1055/a-1282-1156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 45 |
Stölzel U, Stauch T, Kubisch I. [Porphyria]. Internist (Berl) 2021;62:937-51. [PMID: 34185109 DOI: 10.1007/s00108-021-01066-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Linenberger M, Fertrin KY. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP. Hematology Am Soc Hematol Educ Program 2020;2020:400-10. [PMID: 33275677 DOI: 10.1182/hematology.2020000124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 47 |
To-Figueras J, Wijngaard R, García-Villoria J, Aarsand AK, Aguilera P, Deulofeu R, Brunet M, Gómez-Gómez À, Pozo OJ, Sandberg S. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. J Inherit Metab Dis 2021;44:961-71. [PMID: 33861472 DOI: 10.1002/jimd.12391] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 48 |
Gill L, Burrell S, Chamberlayne J, Lombardelli S, Mora J, Mason N, Schurer M, Merkel M, Meninger S, Ko JJ. Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study. Orphanet J Rare Dis 2021;16:187. [PMID: 33902669 DOI: 10.1186/s13023-021-01816-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Syed YY. Givosiran: A Review in Acute Hepatic Porphyria. Drugs 2021;81:841-8. [PMID: 33871817 DOI: 10.1007/s40265-021-01511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 50 |
Anderson KE, Lobo R, Salazar D, Schloetter M, Spitzer G, White AL, Young RM, Bonkovsky HL, Frank EL, Mora J, Tortorelli S. Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians. Am J Med Sci 2021;362:113-21. [PMID: 33865828 DOI: 10.1016/j.amjms.2021.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S; European Liver and Intestine Transplant Association. Liver Transplantation for Acute Intermittent Porphyria. Liver Transpl 2021;27:491-501. [PMID: 33259654 DOI: 10.1002/lt.25959] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 52 |
Souza PVS, Badia BML, Farias IB, Gonçalves EA, Pinto WBVR, Oliveira ASB. Acute hepatic porphyrias for the neurologist: current concepts and perspectives. Arq Neuropsiquiatr 2021;79:68-80. [PMID: 33656101 DOI: 10.1590/0004-282X20200096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 53 |
Buendía-Martínez J, Barreda-Sánchez M, Rodríguez-Peña L, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, Serrano-Antón AT, Pérez-Tomás ME, Gil-Ferrer R, Avilés-Plaza F, Glover-López G, Carazo-Díaz C, Guillén-Navarro E. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients. Orphanet J Rare Dis 2021;16:106. [PMID: 33639982 DOI: 10.1186/s13023-021-01742-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 54 |
Agarwal S, Habtemarium B, Xu Y, Simon AR, Kim JB, Robbie GJ. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels. JIMD Rep 2021;57:85-93. [PMID: 33473344 DOI: 10.1002/jmd2.12173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 55 |
Kaftory R, Edel Y, Snast I, Lapidoth M, Mamet R, Elis A, Hodak E, Levi A. Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias. Mol Genet Metab Rep 2021;26:100707. [PMID: 33489763 DOI: 10.1016/j.ymgmr.2021.100707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Bustad HJ, Kallio JP, Vorland M, Fiorentino V, Sandberg S, Schmitt C, Aarsand AK, Martinez A. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators. Int J Mol Sci 2021;22:E675. [PMID: 33445488 DOI: 10.3390/ijms22020675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 57 |
Wilson-Baig N, Badminton M, Schulenburg-Brand D. Acute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks. BJA Educ 2021;21:66-74. [PMID: 33889432 DOI: 10.1016/j.bjae.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 58 |
Massachi S, Epstein J, Hurd J, Bonkovsky HL. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). J Med Econ 2020;23:1441-9. [PMID: 33043761 DOI: 10.1080/13696998.2020.1835306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Kazamel M, Desnick RJ, Quigley JG. Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management. Curr Neurol Neurosci Rep 2020;20:56. [PMID: 33026560 DOI: 10.1007/s11910-020-01078-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 60 |
Scott LJ. Givosiran: First Approval.Drugs. 2020;80:335-339. [PMID: 32034693 DOI: 10.1007/s40265-020-01269-0] [Cited by in Crossref: 165] [Cited by in F6Publishing: 172] [Article Influence: 55.0] [Reference Citation Analysis]
|
| 61 |
Solares I, Tejedor M, Jericó D, Morales-Conejo M, Enríquez de Salamanca R, Fontanellas A, Tejedor-Jorge A. Management of hyponatremia associated with acute porphyria-proposal for the use of tolvaptan. Ann Transl Med 2020;8:1098. [PMID: 33145317 DOI: 10.21037/atm-20-1529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 62 |
Ventura P. When awareness makes the difference: diagnosing and treating the acute hepatic porphyrias. Intern Emerg Med 2021;16:25-7. [PMID: 32623559 DOI: 10.1007/s11739-020-02421-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 63 |
Cohen AM, Chamberlin S, Deloughery T, Nguyen M, Bedrick S, Meninger S, Ko JJ, Amin JJ, Wei AJ, Hersh W. Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria. PLoS One 2020;15:e0235574. [PMID: 32614911 DOI: 10.1371/journal.pone.0235574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 64 |
Edel Y, Mamet R, Cohen S, Shepshelovich D, Levi A, Sagy I. The clinical importance of early acute hepatic porphyria diagnosis: a national cohort. Intern Emerg Med 2021;16:133-9. [PMID: 32372331 DOI: 10.1007/s11739-020-02359-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 65 |
Parra-Guillen ZP, Fontanellas A, Jiang L, Jericó D, Martini P, Vera-Yunca D, Hard M, Guey LT, Troconiz IF. Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies. Br J Pharmacol 2020;177:3168-82. [PMID: 32133631 DOI: 10.1111/bph.15040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 66 |
Cohen A, Chamberlin S, Deloughery T, Nguyen M, Bedrick S, Meninger S, Ko JJ, Amin J, Wei A, Hersh W. Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria.. [DOI: 10.1101/2020.04.09.20052449] [Reference Citation Analysis]
|
| 67 |
Baravelli CM, Aarsand AK, Sandberg S, Tollånes MC. Sick leave, disability, and mortality in acute hepatic porphyria: a nationwide cohort study. Orphanet J Rare Dis 2020;15:56. [PMID: 32085780 DOI: 10.1186/s13023-019-1273-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 68 |
Bronisch O, Stauch T, Haverkamp T, Beykirch MK, Petrides PE. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families. Ann Hematol 2019;98:2683-91. [DOI: 10.1007/s00277-019-03831-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
